Ke Hou generated a compound that prevents tau aggregation in the murine brain, but the potential Alzheimer’s disease therapy ...

Immune cells in the brain called microglia can partially break down large amyloid plaques characteristic of Alzheimer's disease by latching on to them, forming a sort of external stomach and releasing ...

Alzheimer’s disease is the most prevalent form of dementia and is primarily characterized by the accumulation of β-amyloid and phosphorylated tau proteins in the brain, along with the degeneration of ...

Preclinical studies have shown AT-02 is able to bind to multiple amyloid types and can induce macrophage mediated amyloid phagocytosis and removal. The Food and Drug Administration has granted Orphan ...

EMA’s human medicine committee recommends marketing approval for acoramidis for treatment of transthyretin amyloid cardiomyopathy: Berlin Monday, December 16, 2024, 13:00 Hrs [I ...

Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator.

Light chain amyloidosis is caused by plasma cells in the bone marrow that produce more light chain proteins than heavy chain proteins, which ultimately leads to the deposition of amyloid fibrils ...

in Mexico has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI ® ” (lecanemab) for the treatment of early Alzheimer’s disease (AD)*. LEQEMBI selectively binds ...

What did we learn during Summit’s bonus year of scientific discovery? Here are five sample projects with impactful results. Lighting the way to a new Alzheimer’s treatment Amyloid fibrils are protein ...

additional IR spectra obtained from fibrils generated as a result of co-aggregation and cross-seeding experiments at different time points, AFM-IR of IAPP seeds used for cross-seeding experiment, ...